CCR-TOCa | |||||||
---|---|---|---|---|---|---|---|
Index | Reference | Agent A | Agent B | Description | Quality high (H) or medium (M) | Comparative outcome (A vs B) | Year |
A | [27] | Doripenem mITT 85.9 % (140/163) | Meropenem mITT 85.3 % (133/156) | R, DB, P3 | H | Noninferior | 2008 |
B | [28] | Tigecycline 86.1 % (441/512) | Imipenem-cilastatin 86.2 % (442/513) | Pooled analysis of two phase 3 trials. | H | Noninferior | 2005 |
C | [29] | Tigecycline 92.4 % (219/237) | Imipenem-cilastatin 88.8 % (198/223) | Subanalysis of the European data from Study B | H | - | 2008 |
D | [30] | Tigecycline 80.6 % (199/247) | Imipenem-cilastatin 82.4 % (210/255) | R, DB, P3 | H | - | 2005 |
E | [31] | Tigecycline mITT 86.5 % (45/52) | Imipenem-cilastatin mITT 97.9 % (47/48) | R, OL, P3 | M | - | 2010 |
F | [32] | Tigecycline 81.8 % (162/198) | Ceftriaxone-metronidazole 79.4 % (150/189) | R, OL | M | Noninferior | 2012 |
G | [14] | Ertapenem 79.3 % (245/311) | Piperacillin-tazobactam 76.2 % (232/304) | R, DB, P3 | H | Equivalent | 2003 |
H | [33] | Piperacillin-tazobactam “Clinical success” 97.3 % (108/111) | Imipenem-cilastatin “Clinical success” 97.1 % (100/103) | R | M/H | - | 2004 |
I | [34] | Piperacillin-tazobactam followed by amoxicillin clavulanate For HAI: 55 % (17/31) | Moxifloxacin For HAI: 82 % (22/27) | R, DB, P3 | M | 2006 | |
J | [35] | Ceftolozane-tazobactam + metronidazole 91.4 % (64/70) | Meropenem 94.3 % (33/35) | R, DB, P2 | M | - | 2014 |
K | [36] | Ceftolozane-tazobactam 83.8 % (399/476) | Meropenem 85.8 % (424/494) | R, DB, P3 | H | Noninferior | |
L | [37] | Ceftazidime-avibactam + metronidazole 91.2 % (62/68) | Meropenem 93.4 % (71/76) | R, P2 | M | - | 2013 |